• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Therapy Areas
  • Neuroscience
  • Rapid Dose Escalation of Quetiapine versus Conventional Escalation in the Treatment of Patients with Acute Schizophrenia, a Multicentre, Double-blind, Parallel group, Randomized Study

Disease
schizophrenia
Drug Name
Seroquel
Generic Name
quetiapine
Sponsor
AstraZeneca
Drug Status
Approved Medicine
Phase
II
Start Date
Jun 15, 2005
Study Name
D1441L00032
Study Id
D1441L00032
ClinicalTrials.gov ID
NCT00254787
Recruiting Status
Closed
Protocol Status
Not Available
Report Status
Not Available

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013